Virtus Biotech Clinical Trials ETF
16 hedge funds and large institutions have $1.99M invested in Virtus Biotech Clinical Trials ETF in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 4 closing their positions.
16% less funds holding
Funds holding: 19 → 16 (-3)
17.88% less ownership
Funds ownership: 34.4% → 16.52% (-18%)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
82% less capital inflows, than outflows
Capital inflows: $824K | Capital outflows: $4.57M
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$824K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.5M |
| 2 |
Rockefeller Capital Management
New York
|
-$722K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$633K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$566K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$82.2K |
BBC Hedge Fund Activity: Q1 2023 in Review
16 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2023, worth a combined $1.99M — down 67% from $6.02M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BBC and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 0 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $824K. The largest seller was Goldman Sachs, exiting entirely with an estimated $2.5M sold.
- 16 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2023, down from 19 in Q4 2022.
- Funds reported $1.99M of Virtus Biotech Clinical Trials ETF stock for Q1 2023, down 67% quarter-over-quarter.
- 1 fund opened new Virtus Biotech Clinical Trials ETF positions in Q1 2023 and 4 closed out, a net change of -3 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2023 was Citadel Advisors, an estimated $824K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q1 2023 was Goldman Sachs, an estimated $2.5M sold.
Based on aggregated 13F filings for Q1 2023.